Why Two Approved Drugs Are Not Enough: The IPF Treatment Gap

Idiopathic pulmonary fibrosis is a chronic, progressive, and fatal interstitial lung disease with a median survival of 2–5 years from diagnosis. Only two pharmacological therapies — pirfenidone and nintedanib — are currently approved, and neither halts disease progression or reverses established fibrosis. This fundamental limitation is the central rationale driving an accelerating wave of pipeline investment in novel molecular targets and combination strategies.

According to patent filings retrieved across multiple jurisdictions, IPF is driven by aberrant fibroblast activation, excessive extracellular matrix (ECM) deposition, and dysregulated signaling through growth factor receptors, cytokine pathways, and lipid mediators. Forced vital capacity (FVC) decline is consistently cited as the principal mortality predictor across multiple filings — and the inadequacy of current monotherapy is the explicit justification for every combination program in this dataset.

The TGF-β/SMAD signaling axis is implicated across virtually every therapeutic approach in this dataset as an upstream driver of myofibroblast differentiation and ECM production. This convergence on a shared upstream pathway explains why combination strategies — rather than single-target agents — are now the dominant IP filing strategy in the field. As noted in a 2024 Genentech WO filing, FVC decline continues despite pirfenidone and nintedanib, providing explicit rationale for novel biologic approaches targeting the OSMRβ and IL-6 receptor pathways simultaneously.

Combination Regimens Dominate the Emerging IPF Patent Landscape

The dominant patent filing strategy in the IPF space is pairing novel agents with already-approved nintedanib or pirfenidone — a pattern that simultaneously acknowledges the insufficiency of monotherapy and layers new IP protection onto established therapeutic anchors. At least eight distinct combination programs are documented in this dataset, spanning small molecule kinase inhibitors, receptor antagonists, metabolic enzyme inhibitors, and dual cytokine biologics.

The Boehringer Ingelheim nintedanib + PDE4B inhibitor (Formula III) program is the most voluminous patent family in this dataset by filing count, spanning AU, EP, BR, CA, IL, NZ, TW, and CN jurisdictions with activity from 2019 to 2025. The PDE4B inhibitor is positioned as complementary to nintedanib, which targets receptor tyrosine kinases (VEGFR, FGFR, PDGFR), and is dosed at 9 mg or 18 mg BID in an oral regimen consistent with Phase II dose-finding parameters. The specificity for PDE4B over PDE4A/D isoforms is highlighted as a tolerability advantage over pan-PDE4 inhibitors.

“Neither pirfenidone nor nintedanib alone achieves maximal inhibitory effect — supporting the rationale for combination therapy that adds LPA1 blockade to approved monotherapy while potentially allowing pirfenidone dose reduction.”

Idorsia Pharmaceuticals’ azetidine LPA1 receptor antagonist program represents the most geographically diverse prosecution cluster for a single novel target in this dataset, with filings in WO, US, AU, CA, MX, NZ, IN, IL, and TW jurisdictions between 2021 and 2026. The US patent grant in 2026 signals late-stage IP maturation and creates a potentially blocking composition claim in a key pharmaceutical market. A triple combination — LPA1 antagonist plus pirfenidone plus nintedanib — is also claimed in CN filings, extending the combination IP reach further.

Key Molecular Targets Driving the Next Wave of IPF Therapies

Beyond the two approved agents, the IPF pipeline encompasses at least 15 distinct molecular targets, ranging from lipid mediator receptors and cyclic nucleotide phosphodiesterases to tumor suppressor pathways and metabolic enzymes. Understanding the mechanistic rationale for each target is essential for IP analysts and drug developers evaluating freedom-to-operate and white-space opportunities.

LPA1 (Lysophosphatidic Acid Receptor 1)

LPA1 is targeted by Idorsia Pharmaceuticals using azetidine-scaffold antagonists of Formula (I), which attenuate TGF-β–mediated myofibroblast activation. In vitro evidence from human lung fibroblasts demonstrates attenuation of α-SMA expression — a key marker of myofibroblast differentiation. The combination with pirfenidone is proposed to allow pirfenidone dose reduction, potentially mitigating its known tolerability burden. This target is validated by NIH-supported preclinical research linking LPA1 signaling to fibroblast proliferation and ECM stiffening.

PDE4B (Phosphodiesterase 4B)

Boehringer Ingelheim’s PDE4B inhibitor program identifies a panel of pharmacodynamic biomarkers — KL-6, SP-D, MMP7, CA-125, osteopontin, CTGF, and vWF — for patient selection and treatment monitoring, consistent with an ongoing or recently initiated clinical program. The selection of PDE4B over pan-PDE4 inhibition is mechanistically significant: PDE4B specificity is designed to reduce the emetic side effects historically associated with broad PDE4 inhibition, a known tolerability barrier for this drug class.

GSK-3β (Glycogen Synthase Kinase 3 Beta)

Actuate Therapeutics describes 9-ING-41, a specific GSK-3β inhibitor, as inhibiting fibrotic pulmonary remodeling and myofibroblast-to-fibroblast differentiation in multiple mouse models. Retrieved results characterize 9-ING-41 as “clinically useful” and “well tolerated even at high doses” based on preclinical data, language implying IND-enabling studies may have been completed. The program is represented by CA and MX filings.

p53/MDM2/uPA–Fibrinolytic Axis

The University of Texas System’s broadly prosecuted patent family (WO, EP, CA, AU, IN, BR, HK, CN) establishes that suppression of p53 in fibrotic lung fibroblasts leads to concurrent induction of uPA/uPAR and repression of PAI-1, driving excessive ECM deposition. Nutlin-3a (an MDM2 inhibitor) and the peptide CSP-4 (SEQ ID NO:1) reverse these changes by restoring p53 protein levels — a mechanistically distinct approach from any approved agent. This is among the most multi-jurisdictional academic patent families in this dataset, with some CN applications remaining pending as of 2024.

EPAC1 (Exchange Protein Directly Activated by cAMP 1)

INSERM and Université Paul Sabatier Toulouse III describe EPAC1 inhibition — using CE3F4 and AM-001 — as a “promising therapeutic strategy” for IPF, with preclinical evidence supported by NIH government funding. EPAC1 functions as an adenylyl cyclase effector in pulmonary fibroblasts, and its inhibition represents a mechanistically distinct approach from TGF-β pathway targeting. The program has active filings in WO (2021) and US (2025).

MetAP2 (Methionine Aminopeptidase 2)

SyndevRx discloses MetAP2 inhibitors in combination with nintedanib for pulmonary fibrosis, with an additional claim to prevent treatment-induced ILD — a meaningful differentiator given that nintedanib itself can cause drug-induced lung injury in some patients. This metabolic enzyme approach represents an emerging strategy at the intersection of oncology and fibrosis biology, with filings in WO and AU jurisdictions as of 2025.

Biologics, RNA Therapeutics, and Precision Medicine Approaches

Beyond small molecules, the IPF pipeline encompasses a diverse range of biologic and nucleic acid modalities targeting immunofibrotic pathways, ECM crosslinking enzymes, and cell-type-specific RNA regulators. These approaches reflect growing recognition that fibrosis is not solely a fibroblast-intrinsic process but involves complex immune-stromal crosstalk.

Anti-OSMRβ Antibody: Vixarelimab (Genentech)

Genentech’s vixarelimab program targets the oncostatin M receptor beta subunit (OSMRβ), alone or in combination with the anti-IL-6R antibody tocilizumab, representing the most recent novel biologic program in this dataset with WO (2024) and US (2026) filings. The dual OSMRβ + IL-6R combination approach implies awareness of prior single-pathway biologic failures in IPF — a field where multiple biologics targeting TGF-β alone have not demonstrated clinical benefit, as documented by EMA regulatory assessments. The 2024 WO filing explicitly cites continued FVC decline despite pirfenidone and nintedanib as the rationale for this novel approach.

Anti-LOXL2 and Anti-PAI-1 Antibodies

Gilead Biologics (formerly) discloses anti-LOXL2 antibodies (including AB0023 and AB0024) that target the lysyl oxidase enzyme responsible for collagen crosslinking and ECM stiffening in fibrotic tissue — a fundamentally different mechanism from growth factor receptor inhibition. Sanofi’s CDR-defined monoclonal antibodies against PAI-1 target the fibrinolytic dysregulation axis upstream of ECM accumulation. Both programs reflect the expansion of antibody-based strategies beyond cytokine neutralization into structural fibrosis biology. According to WHO guidance on rare fibrotic lung diseases, ECM crosslinking represents a validated but underexplored therapeutic target.

RNA-Targeting Approaches: miR-21 and miR-92a-3p

The Technical University of Munich (Technische Universität München) discloses a macrophage-directed miR-21 inhibitor composition for pulmonary delivery — a cell-type-selective RNA therapeutic that distinguishes itself from systemic oligonucleotide delivery by specifically targeting fibrotic lung macrophages, where miR-21 is upregulated. This cell-type specificity is a meaningful innovation over earlier, non-targeted RNA approaches. Separately, Gatehouse Bio discloses miR-92a-3p isoforms and mimics for IPF therapy, paired with a biomarker-based patient stratification strategy, in a 2025 AU filing.

Precision Medicine: Genotype-Stratified NAC Therapy (Cornell University)

Cornell University holds patents for N-acetylcysteine (NAC) therapy in IPF patients stratified by SNPs in the TOLLIP gene (rs3750920) and MUC5B promoter region (rs35705950). This pharmacogenomic approach represents a clinically accessible repositioning strategy for a legacy antioxidant compound — leveraging existing safety data while targeting a genetically defined patient subpopulation. It is one of the most translatable precision medicine signals in this dataset, requiring no novel molecular entity development.

Inhaled Nintedanib: Reformulation for Local Delivery

Avalyn Pharma’s 2025 AU filing describes aerosolized nintedanib and indolinone derivative formulations for local pulmonary delivery, with the potential to reduce systemic adverse effects that limit current oral dosing. The filing describes IND-enabling manufacturing processes, consistent with a pre-IND or early IND stage. This reformulation approach does not require a new active pharmaceutical ingredient but addresses a significant unmet need: the gastrointestinal tolerability burden of oral nintedanib, which leads to dose reduction or discontinuation in a substantial proportion of patients.

Who Is Filing: Assignee and Innovation Landscape

The IPF patent landscape in this dataset is predominantly driven by commercial pharmaceutical companies, with academic institutions contributing mechanistically novel but earlier-stage programs. Understanding the assignee landscape is critical for IP strategists assessing freedom-to-operate and for business development teams identifying partnership targets.

Boehringer Ingelheim International GmbH is the single most active patent filer in this dataset, with sustained portfolio investment spanning 2019–2025 across IL, EP, AU, NZ, BR, CA, CN, TW, and CL jurisdictions for the nintedanib + PDE4B inhibitor combination. Idorsia Pharmaceuticals Ltd is the second most active filer, with the recent US grant (2026) for the LPA1 antagonist combination representing a potentially blocking composition claim. Together, these two organizations hold the most geographically expansive combination portfolios in the PF-ILD space.

Genentech, Inc. represents the leading commercial biologic program with vixarelimab, while academic institutions — the Board of Regents of the University of Texas System, Cornell University, INSERM/Université Paul Sabatier Toulouse III, and Technische Universität München — are generating mechanistically novel preclinical-stage IP in MDM2/p53 restoration, NAC pharmacogenomics, EPAC1 inhibition, and macrophage-targeted RNA therapeutics respectively. These academic programs represent differentiated therapeutic hypotheses not yet addressed by commercial players, offering potential partnering or licensing opportunities.

Clinical-stage biotechs including Actuate Therapeutics (GSK-3β/9-ING-41), SyndevRx (MetAP2), and Gatehouse Bio (miR-92a-3p) occupy the mid-tier, with filings in 2–3 jurisdictions each. The emergence of Shanghai Synvida Biotechnology in the PEAR1 + pirfenidone/nintedanib combination space signals growing interest from Chinese biotech entities in the IPF combination patent landscape, consistent with broader trends documented by WIPO in its annual IP statistics reports on pharmaceutical filings from China.

The strategic implications for IP analysts are clear: freedom-to-operate assessments in the PF-ILD combination space must account for the near-universal geographic reach of the Boehringer Ingelheim and Idorsia portfolios. Any novel agent intended for combination use with nintedanib or pirfenidone will need to navigate these composition-of-matter and method-of-treatment claims across multiple jurisdictions. The PatSnap innovation intelligence platform, used by 18,000+ customers across 120+ countries, provides the cross-jurisdictional patent mapping required for this type of analysis.